Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Elevatebio Technologies Inc. maintains a company patent portfolio with 3 pending office actions currently on record. These matters are situated within the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is distributed across 3 distinct examiners and 3 distinct art units.
The busiest examiner for this company is SALVOZA, M FRANCO G, who is managing 1 busiest examiner pending action. Although SALVOZA, M FRANCO G is identified as the busiest, the 3 pending office actions are split among 3 distinct examiners. This distribution indicates that each pending matter is being reviewed by a different individual.
The Biotechnology & Pharmaceuticals technology area covers all 3 distinct art units involved in the company's current prosecution. With 3 pending office actions, the portfolio shows more activity than those with a single action. The 1 busiest examiner pending action is just one part of the company's broader engagement with the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18859955 | PRODUCTION OF RNA POLYNUCLEOTIDES ENCODING PICORNAVIRUS | SALVOZA, M FRANCO G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004151 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING USING CIRCULAR RNA | ROGERS, ERIC JASON | 7d |
| 18859955 | PRODUCTION OF RNA POLYNUCLEOTIDES ENCODING PICORNAVIRUS | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18859955 | PRODUCTION OF RNA POLYNUCLEOTIDES ENCODING PICORNAVIRUS | SALVOZA, M FRANCO G | 1653 | §103§112 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18004151 | COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING USING CIRCULAR RNA | ROGERS, ERIC JASON | 1638 | §102§103§112DP | Final Rejection | 7d | Pending | Jan 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElevatebio Technologies Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
M Franco G Salvoza has the most, with 1 of Elevatebio Technologies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
